Small molecule signal transduction inhibitors for the treatment of solid tumors

Alexandra Leary1, Stephen R D Johnston

  • 1The Royal Marsden Hospital, London, UK.

Cancer Investigation
|July 31, 2007
PubMed

Insights

Novel small molecule therapies target cancer's molecular pathways. This review covers signal transduction inhibitors and clinical trial strategies for these targeted cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer pathogenesis understanding drives novel therapy development.
  • Targeting aberrant molecular pathways distinguishes cancer cells.
  • Small molecules interfere with signaling cascades.

Purpose of the Study:

  • Review small molecule signal transduction inhibitors.
  • Discuss agents in various developmental stages.
  • Address clinical trial design for targeted agents.

Main Methods:

  • Literature review of small molecule inhibitors.
  • Analysis of targeted therapy development.
  • Examination of clinical trial strategies.

Main Results:

  • Small molecules target diverse cellular pathways.
  • Inhibitors are in multiple stages of development.
  • Strategic clinical trial design is crucial.

Conclusions:

  • Small molecule inhibitors represent a promising therapeutic strategy.
  • Targeted agents require careful clinical trial planning.
  • Advancements in understanding cancer signaling pathways are key.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...